CTAD21: Global Dementia Cases Forecasted to Triple by 2050

The 14th Clinical Trials on Alzheimer‘s Disease (CTAD - Boston-Nov 9-13) conference started yesterday with Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research awarded to Ron Peterson, MD, PhD, in recognition for his extensive contributions to the advancement of AD Clinical Trials. Congrats Ron!

CTAD focuses entirely on AD therapeutic trials with Thought Leaders in AD research getting together with the objective of speeding the development of effective treatments to fight this devastating disease.

From Alz.org Global Prevalence of Dementia Expected to Grow Rapidly Through 2050

To more accurately forecast global dementia prevalence and produce country-level estimates, Emma Nichols, MPH, a researcher with the Institute for Health Metrics and Evaluation at the University of Washington School of Medicine, and colleagues leveraged data from 1999 to 2019 from the Global Burden of Disease (GBD) study, a comprehensive set of estimates of health trends worldwide.

Nichols and team found dementia would increase from an estimated 57.4 million cases globally in 2019 to an estimated 152.8 million cases in 2050.

The highest increases were observed in Eastern sub-Saharan Africa, North Africa and the Middle East.

“These estimates will allow policymakers and decision makers to better understand the expected increases in the number of individuals with dementia as well as the drivers of these increases in a given geographical setting,” Nichols said. “The large anticipated increase in the number of individuals with dementia emphasizes the vital need for research focused on the discovery of disease-modifying treatments and effective low-cost interventions for the prevention or delay of dementia onset.”